Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
279
-
Total 13F shares, excl. options
-
67.5M
-
Shares change
-
+2.61M
-
Total reported value, excl. options
-
$3.44B
-
Value change
-
+$102M
-
Put/Call ratio
-
1.38
-
Number of buys
-
132
-
Number of sells
-
-152
-
Price
-
$51.76
Significant Holders of Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) as of Q2 2022
371 filings reported holding NTLA - Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2022.
Intellia Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NTLA) has 279 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67.5M shares
of 108M outstanding shares and own 62.65% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (9.51M shares), VANGUARD GROUP INC (6.51M shares), BlackRock Inc. (5.89M shares), FMR LLC (3.31M shares), STATE STREET CORP (3.14M shares), Nikko Asset Management Americas, Inc. (2.78M shares), Sumitomo Mitsui Trust Holdings, Inc. (2.78M shares), VIKING GLOBAL INVESTORS LP (2.23M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.05M shares), and ALLIANCEBERNSTEIN L.P. (1.7M shares).
This table shows the top 279 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.